Tyra Biosciences shares drop 22% after bladder cancer Phase 2 data
Tyra Biosciences stock fell 22% after Phase 2 trial data for dabogratinib in 44 adults with early-stage non-muscle invasive bladder cancer failed to inspire confidence.
Tyra Biosciences is challenging Johnson & Johnson in the development of a next-generation treatment for a common type of bladder cancer, but the latest data for its experimental pill did not inspire confidence. The Phase 2 trial evaluated dabogratinib in 44 adults with early-stage non-muscle invasive bladder cancer.